Fda, Covıd-19, Covıd-19 Vaccine, Booster Shot, Vaccine Booster, Fda Approval, Johnson & Johnson, Moderna

Fda, Covıd-19

COVID-19 Live Updates: FDA committee approves second Johnson & Johnson dose

An FDA expert panel vote to approve a Johnson & Johnson booster shot two months after the first dose. Follow Newsweek's liveblog for all the latest.

10/15/2021 9:03:00 PM

The FDA Vaccines and Related Biological Products Advisory Committee voted unanimously to recommend emergency authorization of a second Johnson & Johnson dose. More from our live blog:

An FDA expert panel vote to approve a Johnson & Johnson booster shot two months after the first dose. Follow Newsweek's liveblog for all the latest.

Committee member says Johnson & Johnson is"better as a two-dose vaccine"Several members of the committee are questioning if the proposed Johnson & Johnson booster dose is more of a second dose.Johnson & Johnson is presenting the second dose as a booster to the one-shot vaccine and is not looking to change its authorization to a two-dose vaccine.

US Customs officials seize nearly 4,000 bongs at DC airport New York Declares State of Emergency to Combat Omicron Variant Nashville police: 3 dead, 4 wounded in apartment shooting | AP News

Committee member Dr. Eric Rubin, editor-in-chief of The New England Journal of Medicine, said the company should focus on a booster dose two months after the first dose."If the vaccine isn't adequate, then it should be boosted in everybody," Rubin said. He noted that the data for a six-month interval is slim.

"I'm not sure why you're asking for an indication that would apply to millions of patients with a data set that includes 17 patients."Dr. Paul Offit, a vaccine expert from Children's Hospital of Philadelphia, agreed with Rubin and said the Johnson & Johnson vaccine"was always a two-dose vaccine." headtopics.com

"I think it's better as a two-dose vaccine," he said,"it would be hard to recommend this as a single-dose vaccine at this point."13:08 PM EDTCDC data suggests Johnson & Johnson vaccine has low hospitalization efficacyDuring the commission discussion, FDA's Dr. Peter Marks suggests other show shows Johnson & Johnson vaccine has a lower effectiveness for emergency room visits and hospitalizations compared to mRNA vaccines.

The CDC's Amanda Cohn supported that notion, saying the effectiveness of protection with a single dose of the Johnson & Johnson vaccine is not the same as the protection from the Moderna or Pfizer vaccines."In our hospitalization network, so in our active surveillance that looks at vaccine effectiveness in hospitalized individuals, we demonstrated that the Janssen vaccine was only 68 percent effective against hospitalization, and this is in adults greater than 18 years of age without immunocompromising conditions, which is both lower than what we saw from that real-world effectiveness presentation and it is also substantially lower than the mRNA vaccines are against hospitalization even with the waning," Cohn said.

"Additionally there was some other data to suggest that real-world effectiveness is hovering more in the 50 percent to 60 percent [range], and this is from some data from a different surveillance system," she added.12:25 PM EDTFDA suggests"there is more data that is out there" on the Johnson & Johnson booster

The FDA suggests Johnson & Johnson is not telling the committee the whole story on booster shot efficacy.FDA's Dr. Peter Marks told the committee Johnson & Johnson may not be telling the whole story."There is more data that is out there than what we are seeing," he said."There are data suggesting the effectiveness of the vaccine is actually less robust than the company's presentation here." headtopics.com

Chess is sexy again. But for Magnus Carlsen, it's business as usual at the World Chess Championship Panel OKs bid to demolish Wright Brothers' 1st bike shop | AP News Victims and prosecutors see Ghislaine Maxwell as 'center' of Epstein's scheme ahead of trial

Some of the data sets were very small. One of the studies submitted to the FDA looking into the efficacy of the Johnson & Johnson booster after six months included only 17 people. Read more: Newsweek »

Jury finds Kyle Rittenhouse not guilty on all counts

A Wisconsin jury found Kyle Rittenhouse not guilty on all counts after the Illinois teenager shot and killed two men and wounded a third at a protest last year.

FDA to take up Moderna, J&J Covid-19 booster questions this weekVaccine advisers to the FDA meet Thursday and Friday of this week to tackle the next round of questions about booster vaccines for Covid-19 — and they might be seeing the first trickle of data on mix-and-match boosters. blimey mix N match 😂 the only mix N match I'm getting is woolworths .. .. . Never Forget

COVID-19 Live Updates: FDA to hold crunch talks over J&J and Moderna vaccine boostersThe Food and Drug Administration is set to hold crucial meetings over the next two days to decide whether to issue booster shot s of Johnson & Johnson and Moderna COVID vaccines. Follow Newsweek's liveblog for all the latest.

FDA vaccine advisers recommend emergency use authorization for booster dose of Moderna's Covid-19 vaccineVaccine advisers to the US Food and Drug Administration voted unanimously Thursday to recommend emergency use authorization of a booster dose of Moderna 's Covid-19 vaccine. Finally Yea 🎉 Free clots for all.

FDA Panel Votes to Recommend Moderna COVID-19 Booster ShotThe committee of experts followed their previous advice to recommend boosters of the Pfizer-BioNTech vaccine

Abbott Labs unit recalling two COVID-19 lab test kits - FDAA unit of Abbott Laboratories is recalling two COVID-19 laboratory test kits as they can potentially issue false positive results, the U.S. Food and Drug Administration ( FDA ) said on Thursday.

COVID-19 Live Updates: FDA to vote on Johnson & Johnson vaccine booster shot after Moderna approvedAn FDA expert panel will vote on whether to support or oppose a booster shot for the Johnson & Johnson COVID-19 vaccine. Follow Newsweek's liveblog for all the latest.